CORCEPT THERAPEUTICS INC (CORT) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
CORCEPT THERAPEUTICS INC cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $11,226,000.00Stock-based compensation → Operating adjustments reconciliation: $52,459,000.00Accrued and other liabilities, current and non-current → Operating adjustments reconciliation: $24,938,000.00Depreciation and amortization → Operating adjustments reconciliation: $1,461,000.00Prepaid expenses and other current assets → Operating adjustments reconciliation: $1,340,000.00Operating adjustments reconciliation → Net cash from operating activities: $5,545,000.00Operating adjustments reconciliation → Accounts payable: $25,885,000.00Operating adjustments reconciliation → Trade receivables: $17,134,000.00Operating adjustments reconciliation → Accrued research and development expenses: $12,326,000.00Operating adjustments reconciliation → Deferred income taxes: $10,229,000.00Operating adjustments reconciliation → Inventory: $7,536,000.00Operating adjustments reconciliation → Accretion of marketable securities, net: $1,543,000.00Proceeds from sales and maturities of marketable securities → investing reconciliation: $119,312,000.00investing reconciliation → Purchases of marketable securities: $141,283,000.00investing reconciliation → Purchases of property and equipment: $2,729,000.00Net cash used in financing activities → financing reconciliation: $1,277,000.00Proceeds from stock option exercises, net of issuance costs → financing reconciliation: $9,741,000.00Proceeds from purchases under the Employee Stock Purchase Program → financing reconciliation: $6,200,000.00financing reconciliation → Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants: $17,218,000.00Net cash used in investing activities → investing reconciliation: $24,700,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $121,745,000.00Net cash from operating activities → Cash sources and uses: $16,771,000.00Cash sources and uses → Exchange-rate effect: $250,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $112,289,000.00Cash sources and uses → Net cash used in investing activities: $24,700,000.00Cash sources and uses → Net cash used in financing activities: $1,277,000.00Accretion of marketable securities, net: -$1,543,000.00Securities accretion, net−$1.54 MInventory: -$7,536,000.00Inventories−$7.54 MAccounts payable: -$25,885,000.00Accounts payable−$25.89 MDeferred income taxes: -$10,229,000.00Deferred income taxes−$10.23 MStock-based compensation: $52,459,000.00Stock-based compensation+$52.46 MDepreciation and amortization: $1,461,000.00Depreciation & amortization+$1.46 MAccrued and other liabilities, current and non-current: $24,938,000.00Other accrued liabilities+$24.94 MAccrued research and development expenses: -$12,326,000.00Accrued R&D expenses−$12.33 MNet income: $11,226,000.00Net income+$11.23 MTrade receivables: -$17,134,000.00Accounts receivable−$17.13 MPrepaid expenses and other current assets: $1,340,000.00Prepaid & other assets+$1.34 MNet cash from operating activities: $16,771,000.00Operating cash+$16.77 MOperating adjustments reconciliation: $80,198,000.00Proceeds from purchases under the Employee Stock Purchase Program: $6,200,000.00Stock plan proceeds+$6.20 MRepurchases of common stock in connection with Stock Repurchase Program: $0.00Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants: -$17,218,000.00Stock-award tax withholding−$17.22 MProceeds from stock option exercises, net of issuance costs: $9,741,000.00Stock option exercises+$9.74 MNet cash used in financing activities: -$1,277,000.00. Cash required to fund net payments.Financing cash−$1.28 Mfinancing reconciliation: $17,218,000.00Purchases of property and equipment: -$2,729,000.00PP&E purchases−$2.73 MProceeds from sales and maturities of marketable securities: $119,312,000.00Marketable securities proceeds+$119.31 MPurchases of marketable securities: -$141,283,000.00Marketable securities purchases−$141.28 MNet cash used in investing activities: -$24,700,000.00. Cash required to fund net payments.Investing cash−$24.70 Minvesting reconciliation: $144,012,000.00Cash sources and uses: $138,516,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $121,745,000.00Beginning cash$121.75 MEnding cash: Cash, cash equivalents, and restricted cash: $112,289,000.00Ending cash$112.29 MExchange-rate effect: -$250,000.00FX effect−$250.00 KCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$14.04 MOperating cash − cash spent on PP&ECash flow / Net income1.49×Operating cash flow ÷ net incomeNet cash change−$9.46 MEnding cash − beginning cash
Chart details

CORCEPT THERAPEUTICS INC cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
121,745,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
16,771,000 US dollars. Net cash provided.
Accretion of marketable securities, net
negative 1,543,000 US dollars
Inventory
negative 7,536,000 US dollars
Accounts payable
negative 25,885,000 US dollars
Deferred income taxes
negative 10,229,000 US dollars
Stock-based compensation
52,459,000 US dollars
Depreciation and amortization
1,461,000 US dollars
Accrued and other liabilities, current and non-current
24,938,000 US dollars
Accrued research and development expenses
negative 12,326,000 US dollars
Net income
11,226,000 US dollars
Trade receivables
negative 17,134,000 US dollars
Prepaid expenses and other current assets
1,340,000 US dollars
Investing activities
negative 24,700,000 US dollars. Net cash used.
Purchases of property and equipment
negative 2,729,000 US dollars
Proceeds from sales and maturities of marketable securities
119,312,000 US dollars
Purchases of marketable securities
negative 141,283,000 US dollars
Financing activities
negative 1,277,000 US dollars. Net cash used.
Proceeds from purchases under the Employee Stock Purchase Program
6,200,000 US dollars
Repurchases of common stock in connection with Stock Repurchase Program
0 US dollars
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants
negative 17,218,000 US dollars
Proceeds from stock option exercises, net of issuance costs
9,741,000 US dollars
Operating adjustment reconciliation
80,198,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
17,218,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
144,012,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 250,000 US dollars
Ending cash on Jun 30, 2026
112,289,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
138,516,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 9,456,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.49×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
16,771,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
2,729,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
14,042,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $5.55M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 16,771,000 US dollars minus 2,729,000 US dollars equals 14,042,000 US dollars.
CORCEPT THERAPEUTICS INC (CORT) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!